机译:Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Div Hematol Oncol, Dallas, TX USA;
Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA;
Univ Cincinnati, Dept Med, Canc Inst, Cincinnati, OH USAMcGill Univ, Hlth Ctr, Cedars Canc Ctr, Div Hematol, Montreal, PQ, CanadaMed Univ South Carolina, Div Hematol Oncol, Charleston, SC 29425 USAPharmacycl LLC, Sunnyvale, CA USACleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USAMt Sinai Sch Med, Dept Hematol & Med Oncol, 1 Gustave Levy Pl,Box 1185, New York, NY 10029 USAVanderbilt Univ, Med Ctr, Dept Hematol & Oncol, Nashville, TN USADuke Univ Hlth Syst, Div Hematol Malignancies & Cellular Therapy, Durham, NC USACity Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CAColorado Blood Canc Inst, Dept Hematol Oncol, Denver, CO USAWeill Cornell Med, Dept Med Oncol, New York, NY USAUniv Nebraska Med Ctr, Div Oncol & Hematol, Omaha, NE USAAtrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA;
ibrutinib; carfilzomib; Bruton's tyrosine kinase inhibitor; multiple myeloma;